Get the Stockscreener App
4.41
0.23%
-0.010
After Hours:
4.42
0.010
+0.23%
An 2 Therapeutics Inc stock is traded at $4.41, with a volume of 130.09K.
It is down -0.23% in the last 24 hours and up +15.45% over the past month.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
See More
Previous Close:
$4.42
Open:
$4.39
24h Volume:
130.09K
Relative Volume:
0.40
Market Cap:
$158.83M
Revenue:
-
Net Income/Loss:
$-34.55M
P/E Ratio:
-3.9931
EPS:
-1.1044
Net Cash Flow:
$-31.28M
1W Performance:
-12.33%
1M Performance:
+15.45%
6M Performance:
+312.15%
1Y Performance:
+320.00%
1-Day Range:
$4.30
$4.50
1-Week Range:
$4.30
$5.125
52-Week Range:
$1.00
$6.9099
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Name
An 2 Therapeutics Inc
Sector
Industry
Phone
(650) 331-9090
Address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Compare ANTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
4.41 | 174.32M | 0 | -34.55M | -31.28M | -1.1044 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-24 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-03-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Apr-02-24 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-13-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-12-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-12-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-12-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
View All
An 2 Therapeutics Inc Stock (ANTX) Latest News
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - BioSpace
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress - Business Wire
Kymera Therapeutics (KYMR) Extends Rally On Sanofi Milestone And Lupus Data - StocksToTrade
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.15, Implies 2% Downside - TradingView
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st
SYRE Stock Climbs As TL1A Data Ignite Analyst Upgrades - StocksToTrade
APGE Stock Climbs As Street Backs Zumilokibart Momentum - StocksToTrade
Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PR Newswire
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P - GlobeNewswire
Spyre Therapeutics (NASDAQ: SYRE) posts positive Phase 2 SPY002 ulcerative colitis data - Stock Titan
Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise - StocksToTrade
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - GlobeNewswire
TGTX Stock Surges As Briumvi Pipeline Momentum Accelerates - StocksToTrade
82% of myasthenia gravis patients improved in early BRIUMVI shot test - Stock Titan
Tango Therapeutics Announces Combination of Vopimetostat - GlobeNewswire
Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron - Yahoo Finance
Autobahn Therapeutics Reports Positive Phase 2 Topline Data for Elunetirom in Bipolar Depression, Demonstrating Rapid, Robust, and Durable Antidepressant Effects - Business Wire
Tenaya to unveil TN-201 gene therapy HCM trial data June 3, 2026 - Stock Titan
Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Business Wire
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - Business Wire
Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting - Business Wire
Monopar Therapeutics Presents Phase 2 Data for ALXN1840 at EASL Congress 2026, Demonstrating Liver Disease Stabilization and Neurological Improvements in Wilson Disease Patients - Quiver Quantitative
Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease - PR Newswire
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic DermatitisSlideshow (NASDAQ:APGE) 2026-05-30 - Seeking Alpha
Monopar Therapeutics (MNPR) shares Phase 2 Wilson disease data at EASL 2026 - Stock Titan
C4 Therapeutics, Inc. unveils Phase 2 trial progress for cemsidomide at ASCO26 - Traders Union
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - PR Newswire
Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout - PR Newswire
This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday - Benzinga
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - BioSpace
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting - GlobeNewswire
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire
Relay Therapeutics (Nasdaq: RLAY) shares early zovegalisib vascular anomaly data - Stock Titan
Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV Therapy - GlobeNewswire
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - GlobeNewswire
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVCSlideshow (NASDAQ:TNYA) 2026-05-17 - Seeking Alpha
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s - GlobeNewswire
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26, Implies 2% Upside - TradingView
Encoded Therapeutics Presents New Clinical Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the ASGCT 2026 Presidential Symposium - Business Wire
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 - PR Newswire
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewswire
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-05-09 - Seeking Alpha
Millennium-linked entities file 13G/A for Tenax Therapeutics (NASDAQ: TENX) reporting ~2% stakes - Stock Titan
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Avalo Therapeutics (AVTX) jumps as Phase 2 LOTUS topline results and $375M financing reshape outlook - Quiver Quantitative
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - Business Wire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas - Yahoo Finance
MapLight Therapeutics Completes Enrollment in ZEPHYR Phase 2 Trial for Schizophrenia and Final Patient Visit in IRIS Phase 2 Trial for Autism Spectrum Disorder - Quiver Quantitative
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with - GlobeNewswire
Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study - Yahoo Finance
An 2 Therapeutics Inc Stock (ANTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
An 2 Therapeutics Inc Stock (ANTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Williams Sarah Joanne | Principal Accounting Officer |
Mar 03 '26 |
Sale |
1.06 |
327 |
347 |
66,848 |
| Day Lucy | Chief Financial Officer |
Jan 06 '26 |
Sale |
1.01 |
5,512 |
5,578 |
75,363 |
| Day Lucy | Chief Financial Officer |
Jan 05 '26 |
Sale |
1.00 |
3,295 |
3,305 |
80,875 |
| Prior Stephen David | Chief Strategy Officer |
Jan 05 '26 |
Sale |
1.00 |
3,604 |
3,615 |
61,944 |
| Prior Stephen David | Chief Strategy Officer |
Jan 06 '26 |
Sale |
1.01 |
2,858 |
2,892 |
59,086 |
| Chanda Sanjay | Chief Development Officer |
Jan 06 '26 |
Sale |
1.01 |
5,956 |
6,027 |
75,823 |
| Chanda Sanjay | Chief Development Officer |
Jan 05 '26 |
Sale |
1.00 |
3,295 |
3,305 |
81,779 |
| Eizen Joshua M | See Remarks |
Jan 05 '26 |
Sale |
1.00 |
17,923 |
17,948 |
159,430 |
| Eizen Joshua M | See Remarks |
Jan 06 '26 |
Sale |
1.01 |
6,931 |
7,014 |
152,499 |
| Eizen Joshua M | See Remarks |
Nov 04 '25 |
Sale |
1.14 |
2,819 |
3,214 |
177,353 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):